Piffffft

So, we all know that inspiration matters is useless and going absolutely no where. But let's talk about the real topic here. We've let GSK completely own the COPD market place in terms of access. Their coverage is and has been much better for years now. Anoro is out performing Stiolto by about 8 to 1 nationally for many reasons. Better coverage, MUCH easier to use device, good data, etc. Spiriva HH still gets about 60-70% of scripts. Spiriva in Asthma has been flat for a lot time now. There's really only 2 questions to ask here:

1) how much longer do we all have left here? When Spiriva goes off patent we are going to lose a ton of our business. We do ~2.5 Billion a year as a company. About 1.5 of that comes from spiriva. Stiolto is a worthless pile of crap. SPV in asthma does nothing. What do we have left? Nothing.
2) How could the idiots in Germany have had one of the best selling drugs in the world ever, and after 10+ years of multi-billion dollar sales, come up with Stiolto and Respimat?

Clocks ticking, Not sure on timing. Best guess 9 Months - a year.

 

Everything above is so true. Rumors in CT say October will commence more “Right Sizing”. Who knows when the axe will fall .....COPD is a Theif and GSK & is the arresting officer!
BI Has gone from prince to pauper in the Respiratory arena. Even new products like Utibron and Sebri the handihaler me too drugs that are about to receive favored formulary position over respimat
Maybe there will be a tenth re- launch of Combivent!
How about a Rispimat Nasal to save the day?
Rest in Mist

 

HAHAHAHA!!! Y’all are some pot stirring, clouds are falling foils. Lmao!!
Don’t know if y’all are bitter employees, have been fired or just GSK competitors on here but y’all fed are working this board hard.
Only thing to tell ya is that not that many come on here. Pretty inactive board so you’re just eating time trolling here. You’ve got a decent troll game but it needs work on the wording Chief

 

The OP is correct. What do you think you're gonna be selling here in 1-2 years?

Stiolto? Well it's a 100 mil. a year product and going no where. You don't have 1500 reps nationally for a 100 mil a year product. Try about 100 reps.

Spiriva COPD? Well it's going off patent. 70% of scripts are still HH. Even if 100% were respimat, when HH is generic what do you think managed care is gonna say? You get HH, period, end of story. No superiority data vs. respimat anyway.

Spiriva Asthma? It's been flat for almost a year now. It does a tiny amount of sales.

Either some drastic change is going to have to happen, or there's gonna be layoffs yet again. It's math people. It's not about what you feel about Spiriva or Stiolto. It's been years now, the products aren't going anywhere. So some people will have to be let go.

 

inspiration through perspiration. I’m going to sweat the competition with the Mist. No one can resist the intimidation by inspiration as I flaunt my Mist inhaler. There is only the choice of the Mist.

 

Ugh oh! The A team of ZS will be back soon. No doubt their A team will be the ones working on the Gone to Market follow up.
What’s next? Maybe a new contract associate team? A new call plan? Perhaps a new super co-pay coercion card? How about a nurse to breast feed patient information? HSBS will gain insight and utilization with a hospital kit.
Patients will be propelled with a respimat door mat and a bear eating elephant dung on their doorstep. Time to turn open press

 

http://www.startwithanoro.com/lamalabacomparison/index.html?cc=8E9B2A657E13&pid=

 

Dang. When did that study come out? It’s open label though so it has no integrity

 

the mist shall beat all who dare stand in the way of its cloud full of magical mist.
Turn press Inhale will now become drop squat wipe as inhalation through constipation shall become the mist full battle cry of all those lucky enough to carry the power of the mist.

 

Read the study, it is full of issues.

When they say go your own way, I guess that means they can go their own way with reporting data.

 

Doesn’t matter perception becomes reality and this study is being used everywhere and the product is covered.
You can go your own way - as long as formulary and perception dictate

 

So let's review. Dr.s hate the respimat device. Patients hate the device. But Dr. it has Spiriva in it! Head to head study shows Anoro is better. The triple now has higher sales nationally than stiolto. But BI leadership thinks we don't need a triple. But look at all the inhalers that require high PIF! Do we have any efficacy data to show that any of that matters? Nope. But let's just say that you are a hot blonde and the dr loves you and you brought him his favorite lunch. Fine, he'll write it. So where is it covered? Oh no where? So you're screwed anyway. Face it, the respiratory department doesn't have long left. Why? Because the idiots in Germany didn't get a triple and used the worst device ever and then thought saying, but it has spriva in it would solve everything. 1 year or less, more layoffs.

 

Funny. When I chat with my docs about Combivent, they have nothing bad to say.

Must be we can’t deal with some competitive pressure. Quite an indictment on our sales force. No problem selling Handihaler when nobody was competing with us. Now, we get some push back from other pharma selling a LAMA, and the sky is falling. Abandon ship.

As far as access goes, we have our largest Medicare plan, largest national health plan and 2 largest PBM’s (to name a few) yet we still ‘don’t have any access.’ People on welfare have better excuses.

 

People please focus on the mist. Send just 6 rep approved emails this month and all is well. Do not forget 8 fake calls a day.

 

Open label for 8 weeks, moderate patients - what can you conclude?

 

No coverage. Years later no sales. Products going no where. Time to face reality. Lay offs in 1 year. If you want to disagree show me the math. Face reality. Dr.s hate respimat, and even if they loved it, they couldn't write it anyway. No coverage.

 

Behold the Power of the Mist.
Neither Formulary nor Superiority Study shall impede the heroic respiratory sales division. Prescribers and patients alike will clammer to inspire the mist. Boehringer will remain on T.O.P. Making the respiratory division the darlings of the company. Put on your makeup and be sure to makeup 9 calls a day, pile samples into your offices that still allow you to darken their sample closet and Sell sell close!!! Close the sample closet door overflowing with samples and useful copay cards.
Oh well at least it’s not Pradaxa!

 

does anyone actually believe that THIS is what is going to save our broken resp. franchise? We didn't get a triple, we have no coverage, everyone hates our device. Who has an accurate guess on next layoffs? 1 year sounds about right.

 

My bet is one year too.

 

Could be sooner. Docs will listen to your PIF story, but it is not enough to change their behavior. If the DPIs are approved by the FDA and covered by insurance, they will continue to prescribe them. PIF is BI marketing in their view. And to a great extent, they are correct. No one trusts pharma .